{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:23:55Z","timestamp":1787775835473,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"\n A\n BSTRACT<\/jats:sc>\n <\/jats:title>\n \n Introduction:<\/jats:title>\n Oxidative stress is an important component in the pathogenesis of Alzheimer\u2019s disease (AD).<\/jats:p>\n <\/jats:sec>\n \n Materils and Methods:<\/jats:title>\n A comparative cross-sectional study was conducted on 140 participants who made up 70 subjects diagnosed with AD and 70 controls. Serum levels of F2-isoprostanes and Presenilin 1 were estimated using ELISA. These markers were significantly elevated in the serum of AD patients, suggesting them to be potential biomarkers for early diagnosis and disease progression.<\/jats:p>\n <\/jats:sec>\n \n Aim and Objective:<\/jats:title>\n In this study, the level of F2-isoprostanes and Presenilin 1 was determined in patients clinically diagnosed with AD, thus establishing a possible relationship between heightened markers for oxidative stress and progression of AD.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The results showed significantly elevated levels of F2-isoprostanes (179.38 \u00b1 3.01 pg\/mL vs 85.89 \u00b1 0.97 pg\/mL,\n P<\/jats:italic>\n < 0.0001) and Presenilin 1 (93.26 \u00b1 2.39 ng\/mL vs 49.46 \u00b1 0.78 ng\/mL,\n P<\/jats:italic>\n < 0.0001) in AD patients compared to controls. Additionally, markers of lipid peroxidation, such as malondialdehyde (MDA), were elevated in AD patients, while antioxidant defense mechanisms, including glutathione (GSH) and superoxide dismutase (SOD), were significantly impaired (\n P<\/jats:italic>\n < 0.0001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This study provides compelling evidence that oxidative stress, as shown by elevated levels of F2-isoprostanes and Presenilin 1, plays a crucial role in the onset of AD.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_1786_24","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T03:00:15Z","timestamp":1745550015000},"page":"S384-S387","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Role of Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Clinical Diagnosed Alzheimer\u2019s Diseases"],"prefix":"10.4103","volume":"17","author":[{"given":"Dilip Raj","family":"Timalsina","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Datta Meghe Medical College, Nagpur, Datta Meghe Institute of Higher Education and Research (DU) Sawangi Wardha, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leela","family":"Abichandani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Datta Meghe Medical College, Nagpur, Datta Meghe Institute of Higher Education and Research (DU) Sawangi Wardha, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Ambad","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Jawaharlal Nehru Medical College, Wardha, Datta Meghe Institute of Higher Education and Research (DU) Sawangi Wardha, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"R1-20250513","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease:Causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"R2-20250513","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnagi.2014.00071","article-title":"Possible modification of Alzheimer's disease by statins in midlife:Interactions with genetic and non-genetic risk factors","volume":"6","author":"Shinohara","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"R3-20250513","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuron.2010.05.014","article-title":"Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis:A possible contributing factor to Alzheimer's disease","volume":"66","author":"Cortes-Canteli","year":"2010","journal-title":"Neuron"},{"key":"R4-20250513","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease [published correction appears in N Engl J Med. 2012 Aug 23;367:780]","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250513","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics:A retrospective study","volume":"10","author":"Murray","year":"2011","journal-title":"Lancet Neurol"},{"key":"R6-20250513","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7827(97)00001-5","article-title":"The isoprostanes:Unique bioactive products of lipid peroxidation","volume":"36","author":"Morrow","year":"1997","journal-title":"Prog Lipid Res"},{"key":"R7-20250513","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1074\/jbc.274.16.10863","article-title":"Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway","volume":"274","author":"Chen","year":"1999","journal-title":"J Biol Chem"},{"key":"R8-20250513","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1074\/jbc.274.19.13139","article-title":"Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts","volume":"274","author":"Brame","year":"1999","journal-title":"J Biol Chem"},{"key":"R9-20250513","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease:Causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"R10-20250513","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease:Progress and problems on the road to therapeutics [published correction appears in Science 2002 Sep 27;297:2209]","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"R11-20250513","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease:Progress and problems on the road to therapeutics [published correction appears in Science 2002 Sep 27;297:2209]","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"R12-20250513","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease:A practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R13-20250513","doi-asserted-by":"crossref","first-page":"101049","DOI":"10.1016\/j.arr.2020.101049","article-title":"Brain lipid peroxidation and alzheimer disease:Synergy between the Butterfield and Mattson laboratories","volume":"64","author":"Butterfield","year":"2020","journal-title":"Ageing Res Rev"},{"key":"R14-20250513","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-022-00961-5","article-title":"Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment:A meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Alzheimers Res Ther"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1786_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:43:44Z","timestamp":1787773424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1786_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":14,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_1786_24","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"2024-11-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}